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ABSTRACT Sentinel lymph node biopsy (SLNB) is an established method for 
the assessment of tumor aggressiveness in patients with primary cutaneous 
melanoma (PCM). To improve the criteria for the selection of SLNB candidates, 
the aim of our study was to determine clinico-pathohistological parameters 
that can serve as predictors of metastatic progression. We retrospectively eval-
uated all available clinico-pathohistological parameters in 844 patients with 
PCM diagnosed between January 1, 2005 and December 31, 2010. SLNB was 
conducted in 484 (57.3%) patients, 122 (14.5%) of whom had a positive node. 
The association between predictors and SLNB outcomes (positive SLNB and 
metastatic development) was tested using logistic regression analysis. The 
main predictors of positive SLNB were Breslow thickness (adjusted odds ratio 
(AOR)=1.22; 95% confidence interval (CI)=1.11-1.33), Clark levels (AOR=1.78; 
95% CI=1.31-2.40), ulceration (AOR=3.1; 95% CI=1.65-5.81), microsatellitosis, 
gender, and tumor localization. The predictors of metastatic spread were 
Breslow thickness (AOR=1,69; 95% CI=1.51-1.89), Clark level (AOR=3.59; 95% 
CI=2.79-4.62), nodular type of melanoma (AOR=8.21; 95% CI=1.70-39.53), 
ulceration, mitotic rate, microsatellitosis, gender, and tumor localization. It 
seems that these parameters should be taken into consideration when select-
ing patients for SLNB since tumor thickness is not a sufficient predictor of SLNB 
outcome, particularly in case of very thin lesions. 
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INTRODUCTION
In many countries, including Croatia, primary cu-
taneous melanoma (PCM) has an increasing mortality 
rate, and an even more rapidly increasing incidence 
rate, the latter probably attributable to improved di-
agnostics of thin minimally invasive melanoma (1-5). 
An established method for assessing the presence 
of nodal metastases, with a low risk of postoperative 
complications, is sentinel lymph node biopsy (SLNB) 
(6,7,8). However, in about 80% of the cases, sentinel 
biopsy yields a negative result, which suggests a need 
for better candidate selection criteria to decrease the 
number of unnecessary sentinel biopsies (9).
Tumor thickness is a generally accepted reliable 
prognostic parameter but it has been shown that 
very thin lesions behave differently from thick lesions 
(10). This is why other pathohistological and clinical 
parameters have to be used in the selection of can-
didates for SLNB, particularly in the case of thin PCM 
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(11,12). Recent research on novel melanoma mo-
lecular markers has obtained promising results, but 
we should continue searching for easier and simpler 
ways to screen the candidates for SLNB and follow up 
those with higher metastatic potential (12,13). This 
research is an extension of our study performed on 
melanoma patients between 2005 and 2007, with a 
significant enlargement of our database from 492 to 
844 melanoma patients, during the period 2005-2010 
(14). The main objective of this study was to determine 
whether routinely collected clinico-pathohistological 
data can be reliable predictors of SLNB and metastat-
ic potential in primary cutaneous melanoma. 
PATIENTS AND METHODS 
The study was conducted at the Referent Center 
for Malignant Melanoma of the Republic of Croatia 
over a six-year period, from January 1, 2005 to De-
cember 31, 2010 and included 844 patients with pri-
mary cutaneous melanoma (PCM). This is an exten-
sion of our previous study conducted on 492 mela-
noma patients hospitalized between 2005 and 2007, 
who were followed up for 3-6 years (14). Pathohis-
tological analysis of the primary excised tumor and 
sentinel node were performed at the “Ljudevit Jurak” 
Department of Pathology at the “Sestre Milosrdnice” 
University Hospital. In this study we correlated SLNB 
outcome and metastatic development with age, 
gender, localization, tumor type and thickness, Clark 
level, and other pathohistological parameters of the 
primary excised tumor: ulceration, regression, mitotic 
rate, lymphovascular invasion, lymphocytic infiltrate, 
and presence of microsatellitoses (Table 1).
There were 844 patients diagnosed with PCM, 386 
(45.73%) men and 458 (54.26%) women. The mean 
patient age was 54 years (min 7; max 90). As many as 
52.1% patients had tumors on the trunk, usually on 
the back (38.9%), and 61.6% of them had superficial 
spreading melanoma (SSM). There was an equal num-
ber of patients with Clark 2, 3, and 4 levels (about a 
third of patients with each). A similar distribution was 
found for Breslow thickness I, II, and III (about a third 
of the patients each), covering the majority (83.5%) of 
our patients. The main selection criterion for sentinel 
biopsy was tumor thickness ≥1mm, but some SLNB 
were also performed on the basis of clinical judg-
ment.
Breslow tumor thickness is stratified into stages 
from I to IV and expressed in mm and T1-T4 degrees 
according to TNM classification (15). Thin tumors were 
analyzed separately and divided into subgroups: <0.5; 
0.5-0.75; 0.76-1.0; 1.01-1.25; and 1.26-1.5 mm. Mitotic 
rate (number of mitoses per mm2) was divided into 
four subgroups: no mitoses, one mitosis per mm2, 
two to five per mm2, and more than five mitoses per 
mm2. Lymphocytic infiltration was classified as fol-
lows: no lymphocytic infiltration, scarce infiltration, 
moderately dense infiltration, and dense infiltration. 
The study complied with the Helsinki Declara-
tion, and ethical approval was obtained from the eth-
ics committees of the University of Zagreb, Zagreb 
School of Medicine, and “Sestre Milosrdnice” Univer-
sity Hospital, Zagreb, Croatia.
Statistical analysis
Numerical variables were tested for normality of 
distribution using the Kolmogorov-Smirnov test. For 
ordinal and numerical variables that did not show 
normal distribution, nonparametric tests were used 
(Mann-Whitney or Kruskal-Wallis), while for nominal 
categorical variables chi-square and Fisher’s exact 
test were used. The association between sentinel 
and metastatic outcome and independent variables 
was tested using univariate logistic regression, and 
multiple logistic regression was used to control for 
the confounding effects of age and gender. The level 
of statistical significance was set at α=0.05. STATA/IC 
software version 11.02 was used (StataCorp LP, Col-
lege Station, TX, USA).
RESULTS
SLNB was performed in 484 (63%) patients, 22 
(16%) of whom had a positive node. There were 205 
patients (29.5%) who developed a recurrence and 39 
patients (4.6%) who developed metastatic disease 
despite a negative sentinel biopsy. 
Half of our patients (426 patients or 50.47 %) had 
thin tumors, with thickness less than 1.5 mm, and 184 
patients (43%) from this group underwent sentinel 
biopsy.
In the group of thin tumors, sentinel biopsy was 
positive in 22 patients (12%), and 30 patients (7.65%) 
developed metastatic disease. The group of thinnest 
tumors (<0.5 mm) had the highest proportion of posi-
tive nodes (33.3%) among all tested groups, while the 
group of the thickest tumors (1.26-1.5 mm) had the 
highest proportion of patients with metastatic de-
velopment (23%). As much as 50% of positive nodes 
were found in tumors less than 1 mm. The two thick-
est stratified groups covered as much as 36% of all 
metastatic outcomes. (Table 2).
Seven patients had lymphovascular invasion and 
only four regressions, which was insufficient to in-
clude these parameters into statistical analysis.
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Sentinel biopsy outcome
Sentinel biopsy was performed in 484 (57.34%) pa-
tients, 122 (14.45%) of whom had a positive SLNB, of 
which significantly more men than women (P=0.028), 
with men having a 1.61 times higher risk for a posi-
tive sentinel biopsy outcome (women vs. men odds 
ratio (OR)=0.62; 95% confidence interval (CI)=0.41-
0.94). There was no significant difference according 
to age. Significantly more patients with nodular and 
nevoid melanoma had positive SLNB (P<0.001), but 
logistic regression analysis did not confirm this find-
ing. Patients with tumors on the trunk had the high-
est risk for positive SLNB – the front trunk (adjusted 
OR (AOR)=5.6; 95% CI=1.53-20.55) and the back trunk 
including the gluteal region (AOR=4.43; 95% CI=1.29-
15.27). Higher risk of sentinel lymph node positivity 
was also associated with higher Clark levels of inva-
sion (AOR=1.78; 95% CI=1.13-2.4) and Breslow tumor 
thickness (AOR=1.22; 95% CI=1.11-1.33).  
When we stratified thin tumors into five groups, 
increase in tumor thickness did not lead to an in-
crease in the risk of positive sentinel biopsy: 0.5-
0.75 mm (AOR=0.46; 95% CI=0.09-2.45); 0.76-1.00 
mm (AOR=0.23; 95% CI=0.06-0.88); 1.01-1.25 mm 
(AOR=0.17; 95% CI=0.04-0.75); 1.26-1.50 mm 
(AOR=0.18; 95% CI=0.04-0.91) (Table 3).
Regarding other pathohistological parameters, a 
significant association with SLNB positivity was found 
for the presence of ulceration (P<0.001), higher mi-
totic rate (P=0.018), microsatellitosis (P<0.031), and 
the presence of lymphocytic infiltration (P=0.037), 
but not for the presence of lymphocapillary invasion 
(P=0.575). Logistic regression analysis confirmed that 
ulceration was a strong predictor of positive sentinel 
biopsy outcome (AOR=3.1; 95% CI=1.65-5.81), as well 
as the presence of microsatellitoses (AOR=2.86; 95% 
CI=1.1-7.41), indicating a three times greater prob-
ability of a positive sentinel biopsy outcome.
Since only routine staining (hematoxylin and eo-
sin (HE) stain) was performed in our pathohistological 
laboratory, too few lymphocapillary invasions (N=7) 
were detected to be included into statistical analysis. 
Only four of these patients experienced recurrence 
and none had undergone SLNB. The results of logis-
tic regression analysis for positive SLNB outcome are 
summarized in Table 3.
Outcome of metastatic development
At the end of study period, 205 patients (24.28%) 
experienced some type of disease progression (posi-
tive local or distant lymph nodes, presence of cuta-
neous or distant visceral metastases). Men had an 
almost two times higher probability of developing 
metastatic disease than women (P<0.001) (OR=0.51; 
Table 2. Thin tumors (<1.5 mm)
sentinel lymph node biopsy
neg pos pos % Total
Thin tm (mm) <0.5 10 5 33.33 15
0.5-0.75 15 3 16.67 18
0.76-1 60 7 10.45 67
1.01-1.25 44 4 8.33 48
1.26-1.5 33 3 8.33 36
Total 162 22 184
metastases
neg pos pos % Total
Thin tumors (mm) <0.5 105 5 4.55 110
0.5-0.75 99 5 4.81 104
0.76-1 97 8 7.62 105
1.01-1.25 41 6 12.77 47
1.26-1.5 20 6 23.08 26
Total 362 30 392





neg 134 0 134
pos 6 22 28
Total 140 22 250
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95% CI=0.37-0.71). Nodular melanoma showed the 
greatest aggressiveness (AOR=8.21; 95% CI=1.70-
39.53), with metastatic development observed in 
62.6% of cases, followed by nevoid melanoma at 
50% and ALM at 41.7% of cases (P<0.001). A signifi-
cant association was found between the localization 
of the primary tumor (P<0.001) and development of 
metastatic disease – 66.7% of acral localization cases 
Table 3. Logistic regression analysis for positive outcome of sentinel lymph node biopsy
Feature OR 95%CI AOR*** 95%CI
Gender (women vs. men) 0.62* 0.41-0.94 NA NA
Age (years) 1.01 0.996-1.02 NA NA
Localization – head and neck 1 NA 1 NA
Localization – trunk front 5.17* 1.42-19.82 5.6* 1.53-20.55
Localization – trunk back and 
gluteal
4.02* 1.17-13.74 4.43* 1.29-15.27
Localization – arm and shoulder 2.13 0.56-8.07 2.43 0.64-9.32
Localization – leg and hip 2.73 0.77-9.69 3.16 0.87-11.47
Localization – earlobe, subungual. 
and fingers
2.41 0.34-17.04 2.36 0.33-16.82
Localization – eye NA** NA** NA** NA**
Localization – unknown primary 
site
NA** NA** NA** NA**
Type- MIS**** 1 NA 1 NA
Type - SSM**** 0.47 0.04-5.35 0.49 0.04-5.57
Type - NM**** 1.41 0.12-15.91 1.42 0.12-16.11
Type - LMM**** 0.44 0.03-7.67 NA** NA**
Type - ALM**** 2 0.09-44.35 0.46 0.03-8.04
Type - melanoma nevoides NA** NA** NA** NA**
Type – desmoplastic melanoma NA** NA** NA** NA**
Clark classification 1.87* 1.39-2.51 1.78* 1.31-2.40
Breslow thickness (mm) 1.24* 1.14-1.35 1.22* 1.11-1.33
Breslow classification I 1 NA 1 NA
Breslow classification II 0.32* 0.12-0.84 0.33* 0.12-0.87
Breslow classification III 1.18 0.50-2.8 1.16 0.49-2.77
Breslow classification IV 2.40 0.99-5.84 2.24 0.91-5.14
Thin tumors – <0.5 mm 1 NA 1 NA
Thin tumors – 0.5-0.75 mm 0.40 0.08-2.06 0.46 0.09-2.45
Thin tumors – 0.76-1 mm 0.23* 0.06-0.88 0.23* 0.06-0.88
Thin tumors – 1.01-1.25 mm 0.18* 0.04-0.80 0.17* 0.04-0.75
Thin tumors – 1.26-1,5 mm 0.18* 0.04-0.90 0.18* 0.04-0.91
TNM- T1a 1 NA 1 NA
TNM- T1b 0.41 0.10-1.72 0.43 0.10-1.82
TNM- T2a 0.45 0.12-1.69 0.45 0.12-1.67
TNM- T2b 0.63 0.14-2.85 0.61 0.13-2.81
TNM- T3a 0.83 0.12-6.01 0.87 0.12-6.40
TNM- T3b 1.79 0.35-9.13 1.86 0.36-9.58
TNM- T4a 1.88 0.39-9.01 1.92 0.40-9.34
TNM- T4b 3.21 0.83-12.44 3.17 0.80-12.57
Number of mitoses - 0 1 NA 1 NA
Number of mitoses - 1 0.33 0.08-1.28 0.33 0.08-1.29
Number of mitoses - 2-5 1.08 0.36-3.24 1.06 0.35-3.18
Number of mitoses - >5 1.55 0.48-5.03 1.42 0.43-4.68
Ulceration (yes vs. no) 3.27* 1.75-6.08 3.10* 1.65-5.81
Lymphocytic infiltration – none 1 NA 1 NA
Lymphocytic infiltration – scarce 4.67 0.53-41.22 4.14 0.46-37.06
Lymphocytic infiltration – 
moderately dense
2.22 0.26-19.17 2.19 0.25-19.00
Lymphocytic infiltration – dense 1.62 0.19-13.97 1.56 0.18-13.54
Microsatellitosis (yes vs. no) 2.84* 1.11-7.26 2.86* 1.10-7.41
*statistically significant result at the level α=0.05
**perfectly predicts the outcome
***OR standardized for age and gender 
 ****MIS – melanoma in situ; SSM – superficial spreading melanoma; NM – nodular melanoma; LMM – lentigo maligna melanoma; ALM  
 – acrolentiginous melanoma
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metastasized, followed by 36.6% of front trunk lo-
calization cases, 32.7% of leg and hip localization 
cases, and 29.4% of back trunk and gluteal local-
ization cases. Patients with primary tumor localiza-
tion on the trunk and leg had a three times higher 
probability of developing metastatic disease: 
trunk front (AOR=3.29; 95% CI=1.36-7.91); trunk 
back and gluteal region (AOR=2.46; 95% CI=1.10-
5.53); leg (AOR=3.56; 95% CI=1.52-8.35); and patients 
with acral tumor localization (earlobe, subungual, 
fingers) had an almost 11 times higher probability 
(AOR=10.71; 95% CI=2.18-52.68) than patients with 
tumor localization on the head and neck. Higher 
Clark levels of invasion increased the risk of develop-
ing metastatic disease almost four times (AOR=3.59; 
95% CI=2.79-4.62). As many as 84.2% of patients with 
Table 4. Logistic regression analysis for metastatic spread of melanoma
Feature OR 95%CI AOR*** 95%CI
Gender (women vs. men) 0.51* 0.37-0.71 NA NA
Age (years) 1.01 0.99-1.02 NA NA
Localization- head and neck 1 NA 1 NA
Localization – trunk front 3.17* 1.34-7.52 3.29* 1.36-7.91
Localization – trunk back and 
gluteal 2.29* 1.03-5.08 2.46* 1.10-5.53
Localization – arm and shoulder 1.15 0.46-2.86 1.36 0.54-3.42
Localization – leg and hip 2.67* 1.17-6.10 3.56* 1.52-8.35
Localization – earlobe, subungual. 
and fingers 11* 2.27-56.27 10.71* 2.18-52.68
Localization – eye NA** NA** NA** NA**
Localization – unknown primary 
site NA** NA** NA** NA**
Type – MIS*** 1 NA 1 NA
Type – SSM*** 1.08 0.23-5.060 1.11 0.23-5.24
Type – NM*** 8.37* 1.75-40.20 8.21* 1.7-39.53
Type – LMM*** NA** NA** NA** NA**
Type – ALM*** 3.57 0.53-23.95 3.77 0.56-25.51
Type - melanoma nevoides NA** NA** NA** NA**
Type – desmoplastic melanoma NA** NA** NA** NA**
Clark classification 3.66* 2.86-4.71 3.59* 2.79-4.62
Breslow thickness (mm) 1.71* 1.53-1.91 1.69* 1.51-1.89
Breslow classification I 1 NA 1 NA
Breslow classification II 2.58* 1.18-5.67 2.59* 1.17-5.70
Breslow classification III 17.2* 8.46-35 16.80* 8.25-34.25
Breslow classification IV 45.72* 21.15-95.86 43.54* 20.08-94.40
Thin tumors – <0,5mm 1 NA 1 NA
Thin tumors – 0.5-0.75mm 1.06 0.30-3.78 0.99 0.28-3.62
Thin tumors – 0.76-1mm 1.73 0.55-5.48 1.63 0.50-5.27
Thin tumors – 1.01-1.25mm 3.07 0.89-10.62 2.99 0.86-10.36
Thin tumors – 1.26-1.5mm 6.30* 1.75-22.64 6.05* 1.64-22.32
TNM – T1a 1 NA 1 NA
TNM – T1b 0.74 0.20-2.71 0.78 0.21-2.90
TNM – T2a 5.54* 1.78-17.18 5.55* 1.78-17.27
TNM – T2b 11.27* 2.89-43.96 11.60* 2.96-45.46
TNM – T3a 15.50* 2.33-102.90 14.15* 2.08-96.33
TNM – T3b 108.50* 10.59-1111.25 115.18* 11.07-1198.43
TNM – T4a 34.88 7.39-164.68 34.45* 7.25-163.58
TNM – T4b 42.63* 11.67-155.63 40.19* 10.82-149.22
Number of mitoses – 0 1 NA 1 NA
Number of mitoses – 1 0.43 0.14-1.28 0.46 0.15-1.38
Number of mitoses – 2-5 4.64* 2.03-10.60 4.86* 2.11-11.19
Number of mitoses – >5 17.87* 6.87-46.47 16.94* 6.43-44.58
Ulceration (yes vs. no) 8.69* 4.78-15.80 8.54* 4.64-15.71
Lymphocytic infiltration – none 1 NA 1 NA
Lymphocytic infiltration – scarce 1.69 0.46-6.13 1.47 0.39-5.45
Lymphocytic infiltration – 
moderately dense 0.63 0.18-2.17 0.55 0.15-1.94
Lymphocytic infiltration – dense 0.45 0.13-1.59 0.42 0.16-1.47
Microsatellitosis (yes vs. no) 8.02* 3.15-20.43 8.60* 3.34-22.15
*statistically significant result at the level α=0.05
**OR standardized for age and gender 
 ***MIS – melanoma in situ; SSM – superficial spreading melanoma; NM – nodular melanoma; LMM – lentigo maligna melanoma; ALM  
 – acrolentiginous melanoma
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Clark level V developed metastatic disease. Increased 
thickness was associated with greater metastatic de-
velopment (AOR=1.69; 95% CI=1.51-1.89). Among 
thin tumors (up to 1.5 mm), significantly more tumors 
from the subgroup 1.26-1.5mm developed metasta-
ses (AOR=6.05; 95% CI=1.64-22.32).
The presence of microsatellitosis increased the 
risk of metastatic development (AOR= 2.86; 95% 
CI=1.10-7.41), as well as the presence of ulceration, 
which increased the risk for almost 8.5 times (AOR= 
2.86; 95% CI=1.10-7.41). Increased risk was also found 
for mitotic rate in the group of tumors with 2-5 mi-
toses/mm2 (AOR=4.86; 95% CI=2.11-11.19) and more 
than 5 mitoses/mm2 (AOR=16.94; 95% CI=6.43-44.58) 
compared with the group of tumors with no mitoses. 
Out of the 284 sentinel negative patients, 39 de-
veloped a remote visceral metastasis, suggesting 
a procedural error or passing over the lymph node. 
Lymphocapillary invasion (P=0.221) and recurrence 
(P=0.275) showed no significant correlation with 
metastatic development. Although expected, the as-
sociation with age was not found. The results of logis-
tic regression analysis are summarized in Table 4.
DISCUSSION
Different clinico-pathological parameters have 
been shown to have prognostic value for SLNB posi-
tivity (16,17). For example, the American Joint Com-
mittee on Cancer (AJCC) included mitotic rate and 
ulceration among prognostic factors, which affected 
staging and classification of thin tumors (18). There-
fore, there is a need for uniform criteria for SLNB 
across different health institutions.
Since thick tumors (>4 mm) showed a high inci-
dence of positive lymph nodes (30-40%), we believe 
that SLNB should be conducted even in patients with 
thick tumors who have clinically negative lymph 
nodes (19). However, most primary cutaneous mela-
nomas are thin tumors (0.51-1.00 mm thickness). 
These tumors are usually associated with a low risk 
of disease progression and mortality, but still about 
10% of them result in recurrence and death (10). Our 
study confirmed that thin lesions showed a tendency 
towards aggressive behavior – as much as 12% of pa-
tients with a thin lesion had a positive sentinel node 
and 7.65% of patients with such lesions developed 
metastases. Such results indicate that thickness alone, 
particularly within the group of tumors thinner than 
1.5 mm, is not a reliable prognostic factor and that 
other pathohistological and clinical parameters need 
to be taken into account, such as male gender, nodu-
lar melanoma, localization (particularly trunk and ac-
ral), higher Clark levels, ulceration, and the presence 
of mitoses in primary tumors as well as occurrence of 
microsatellitoses.
It has still not been determined whether SLNB is 
useful in thin melanoma cases (20,21). If we take into 
account the cost of this procedure and risk of possi-
ble complications, it is clear that selection criteria for 
SLNB should be improved. Tumor thickness was not 
found to reliably predict tumor aggressiveness, par-
ticularly in thin tumors (under 1.5 mm). 
The main limitation of our study was the lack of 
routine SLNB in tumors thinner than 1 mm in our in-
stitution; in such cases SLNB was conducted on the 
basis of clinical judgment. Therefore, we did not have 
a representative sample in this category. Still, the oc-
currence of metastases among stratified thin tumors 
was significantly higher in the group of the thickest 
tumors (1.26-1.50 mm).
Some studies report that lymphocapillary inva-
sion and tumor regression predicted a positive sen-
tinel biopsy outcome and the occurrence of metasta-
ses, but we were not able to confirm such finding due 
to small sample size. 
CONCLUSION
Although recent molecular studies have shown 
promising results in the field, clinical and pathohisto-
logical data remain the most cost-effective and sim-
ple way to assess the risk of metastatic occurrence in 
patients with melanoma.  
The contradictory results obtained within the 
group of thin tumors indicate that thickness might 
not be a reliable predictive parameter. Thus, our 
study showed that when deciding whether to con-
duct SLNB we should consider other pathohistologi-
cal factors in addition to tumor thickness and level of 
invasion. These factors are the presence of mitosis, 
ulceration, microsatellitosis, male gender, trunk and 
acral localization, and nodular type of melanoma. We 
also recommend introduction of additional immuno-
histochemical methods into routine work to be able 
to more efficiently assess the predictive value of all 
parameters. There is also a need for further prospec-
tive studies on this topic, especially those focusing on 
thin tumors.
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